TAE Life Sciences, a US-based company that deals with advancing Boron Neutron Capture Therapy (BNCT) for cancer treatment, announced on Wednesday that it has named Dr Deepak 'Dee' Khuntia, MD, FASTRO as its new director.

Dr Khuntia has served as senior vice president of Medical Affairs and chief medical officer at Varian. He has a career spanning decades.

Rob Hill, TAE Life Sciences CEO, said, 'Dr Deepak Khuntia brings unparalleled expertise and leadership in the field of radiation oncology, with an emphasis on many of the same types of cancers we're targeting with BNCT. I'm confident that he'll prove invaluable as we continue to innovate and develop groundbreaking cancer treatment solutions. Dr. Khuntia's presence on our board further validates our commitment to revolutionising radiation oncology and driving mainstream adoption of BNCT as a treatment modality.'